Physicians' Academy for Cardiovascular Education

Initiating PCSK9 mAb after ACS: When and how to start?

10' education - Mar. 22, 2023 - Prof. Wouter Jukema, MD, PhD and Prof. Pasquale Perrone-Filardi, MD, PhD

Interesting developments in the field of PCSK9 inhibition

3' education - Mar. 21, 2023 - Prof. Deepak Bhatt, MD

Implementing precision health for public health using causal AI

3' education - Mar. 21, 2023 - Ami Bhatt, MD

Causal AI can substantially improve the value of polygenic risk score for CVD

3' education - Mar. 21, 2023 - Prof. Brian Ference, MD

Well-designed EHR tools can improve prescribing of MRA in HFrEF

3' education - Mar. 21, 2023 - Amrita Mukhopadhyay, MD

Timing of benefits of intentional weight loss in cardiometabolic disease

5' education - Mar. 20, 2023 - Naveed Sattar, MD, PhD

Findings of a phase 2 trial with aldosteron synthase inhibitor in hypertension

3' education - Mar. 8, 2023 - Prof. Deepak Bhatt, MD

Promising results for oral PCSK9i to proceed to phase 3 trials

3' education - Mar. 8, 2023 - Prof. Christie Ballantyne, MD

Benefit and safety profile of icosapent ethyl in patients with recent ACS

3' education - Mar. 7, 2023 - Prof. Gabriel Steg, MD

Residual inflammatory risk is major driver of CV events and mortality in statin-treated patients

3' education - Mar. 7, 2023 - Prof. Paul Ridker, MD

Early eGFR decline after transitioning to ARNI not associated with adverse outcomes

3' education - Mar. 6, 2023 - Safia Chatur, MD

New evidence-based non-statin treatment to lower LDL-c and CV risk

3' education - Mar. 6, 2023 - Prof. Peter Libby, MD

Assocation between low-carbohydrate high-fat diet and MACE

3' education - Mar. 6, 2023 - Liam Brunham, MD, PhD

Where is bempedoic acid going to fit in?

3' education - Mar. 6, 2023 - Prof. Kausik Ray, MD

Strengths and limitations of phase 3 trial with bempedoic acid

3' education - Mar. 5, 2023 - Prof. Eugene Yang, MD

Protective cardiac effects of statin in patients with lymphoma treated with anthracyclines

3' education - Mar. 5, 2023 - Prof. Marielle Scherrer-Crosbie, MD, PhD

Results of CV outcomes trial with bempedoic acid in statin-intolerant patients

3' education - Mar. 5, 2023 - Prof. Steven Nissen, MD

One-year results of transcatheter tricuspid valve edge-to-edge repair for tricuspid regurgitation

3' education - Mar. 5, 2023 - Kendra Grubb, MD

Revascularization in cardiac surgery

10' education - Feb. 28, 2023 - Lauren Barron, MD, Navin Kapur, MD, Adam DeVore, MD

An urgent call for action to tackle excess adiposity

5' education - Feb. 28, 2023 - Prof. Naveed Sattar, MD, PhD

IL-6 inhibition reduces neutrophil-lymphocyte ratio in patients with CKD and elevated hsCRP

Literature - Mar. 22, 2023 - Adamstein NH, et al. - JAMA Cardiol. 2023

A secondary analysis of the RESCUE trial investigated whether IL-6 inhibition with ziltivekimab, a novel therapeutic monoclonal antibody against IL-6, changes the neutrophil-lymphocyte ratio (NLR) in patients with CKD and elevated hsCRP.

Initiating PCSK9 mAb after ACS: When and how to start?

10' education - Mar. 22, 2023 - Prof. Wouter Jukema, MD, PhD and Prof. Pasquale Perrone-Filardi, MD, PhD
In large RCTs, PCSK9 inhibitors have shown to have great value in patients with ACS, but how do you implement these agents in clinical practice?

In large RCTs, PCSK9 inhibitors have shown to have great value in patients with ACS, but how do you implement these agents in clinical practice?

Beneficial effects of PCSK9i on CV events depend on both hsCRP and Lp(a) levels

Literature - Mar. 21, 2023 - Schwartz GG, et al. - J Am Coll Cardiol. 2022

In this post hoc analysis of the ODYSSEY OUTCOMES trial, the authors demonstrated that the beneficial effects of alirocumab on Lp(a)-associated risk of CV events in patients with ACS are modified by hsCRP.

Interesting developments in the field of PCSK9 inhibition

3' education - Mar. 21, 2023 - Prof. Deepak Bhatt, MD

ACC.23 "The field of LDL-c reduction is very hot", says Deepak Bhatt. He talks about novel ways to lower LDL-c through PCSK9 inhibition, including a new oral agent.

Implementing precision health for public health using causal AI

3' education - Mar. 21, 2023 - Ami Bhatt, MD
What are the results of a study examining use of causal AI for polygenic risk score and family history to predict cardiovascular risk, and how can we use causal AI in the future?

ACC.23 What are the results of a study examining use of causal AI for polygenic risk score and family history to predict cardiovascular risk, and how can we use causal AI in the future?

Causal AI can substantially improve the value of polygenic risk score for CVD

3' education - Mar. 21, 2023 - Prof. Brian Ference, MD
Use of causal AI can improve risk prediction for CVD by polygenic risk scores and thereby provide insight for individualized treatment choices, says Brian Ference.

ACC.23 Use of causal AI can improve risk prediction for CVD by polygenic risk scores and thereby provide insight for individualized treatment choices, says Brian Ference.

Well-designed EHR tools can improve prescribing of MRA in HFrEF

3' education - Mar. 21, 2023 - Amrita Mukhopadhyay, MD
Amrita Mukhopadhyay discusses the BETTER CARE-HF study, which investigated whether an alert or an inbox message delivered via EHR systems to cardiologists, improves prescribing of MRA in patients with HFrEF compared to usual care.

Amrita Mukhopadhyay discusses the BETTER CARE-HF study, which investigated whether an alert or an inbox message delivered via EHR systems to cardiologists, improves prescribing of MRA in patients with HFrEF compared to usual care.

No indication for oral anticoagulation after TAVI: SAPT outperforms DAPT and DOAC-based regimens

Literature - Mar. 20, 2023 - Guedeney P, et al. - Eur Heart J Cardiovasc Pharmacother. 2023

In a network meta-analysis of 7 RCTs, single antiplatelet therapy (SAPT) reduced the bleeding risk following TAVI by 55% compared with dual APT and also direct oral anticoagulants in patients with no indication for chronic oral anticoagulation, with no increase in all-cause death.

Timing of benefits of intentional weight loss in cardiometabolic disease

5' education - Mar. 20, 2023 - Naveed Sattar, MD, PhD
Large scale intentional weight loss in patients with cardiometabolic disease results in changes that are rapid, intermediate or that take longer. Naveed Sattar shares important learnings on this topic to understand and contextualize future trials.

Large scale intentional weight loss in patients with cardiometabolic disease results in changes that are rapid, intermediate or that take longer. Naveed Sattar shares important learnings on this topic to understand and contextualize future trials.

Treatment effects of ARNI in HF independent of eGFR decline during run-in phase

Literature - Mar. 20, 2023 - Chatur S, Claggett BL, McCausland FR, et al. - J Am Coll Cardiol. 2023

Patients with HF may experience a transient decline in eGFR of up to 15-20% after initiation of sacubitril/valsartan. But how does this affect treatment effects? This post hoc analysis of the PARADIGM-HF and PARAGON-HF study offers more insight.

Bempedoic acid reduces hs-CRP, but not fibrinogen and IL-6 in patients with residual inflammatory risk

Literature - Mar. 16, 2023 - Ridker PM, et al. - J Clin Lipidol. 2023

In a secondary biomarker analysis of the CLEAR Harmony trial, bempedoic acid lowered levels of LDL-c and hs-CRP, but not fibrinogen or IL-6, compared with placebo in patients with ASCVD and/or heterozygous familial hypercholesterolemia (HeFH) who had residual inflammatory risk.

Beneficial effects of nonsteroidal MRA on mortality in patients with CKD and T2DM

Literature - Mar. 15, 2023 - Filippatos G, et al. - Eur Heart J Cardiovasc Pharmacother. 2023

In the prespecified FIDELITY analysis, the authors investigated the causes of mortality in patients with CKD and T2DM treated with the nonsteroidal MRA finerenone or placebo.